MARKETS / NASDAQ / BRKR

NASDAQ · LABORATORY ANALYTICAL INSTRUMENTS · LARGE CAP

Bruker Corp. BRKR

17 fiscal years on record · USD · FY2025 reported · SEC filings only

Revenue

$3.4B

▲ 2.1% YoY

Net income

$-8.6M

▼ 107.6% YoY

Free cash flow

$43.3M

▼ 68.2% YoY

In brief

What this company does

Bruker Corporation develops, manufactures, and distributes high-performance scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. Its corporate headquarters are located in Billerica, Massachusetts, and it maintains major technical and manufacturing centers in Europe and North America. Bruker has four reportable segments — Bruker Scientific Instruments ("BSI") BioSpin, BSI CALID, BSI NANO, and Bruker Energy and Supercon Technologies ("BEST") — each comprising several divisions. As of December 31, 2025, Bruker had approximately 11,085 employees worldwide. The BSI BioSpin Segment comprises several divisions, including Magnetic Resonance Spectroscopy, which offers nuclear magnetic resonance and electron paramagnetic resonance products ranging from benchtop to ultra-high field systems. The BSI CALID Segment comprises several divisions, including Bruker Life Sciences Mass Spectrometry, whose instruments are used in research and in pharmaceutical and biotechnology development. The BSI NANO Segment comprises several divisions, including Bruker AXS, which designs, manufactures, and distributes X-ray instruments that determine the characteristics of matter and the three-dimensional structure of molecules.

Written from the business description in BRUKER CORPORATION's annual report to the U.S. Securities and Exchange Commission, filed 27 February 2026. Every sentence was checked against that document before publication.

Growth

USD 3.4B

Revenue, FY2025 · full 17-year series below

Revenue $B Net income $B

FY2025 · Revenue 3.4 · Net income -0.0

Compound annual growth

Revenue

+10.7%

+11.6%

+7.8%

+6.7%

Returned to shareholders

−55.9%

−29.6%

−10.9%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at +11.6% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−0 cents

lost on every revenue dollar

Operating margin Net margin

FY2025 · Operating 2.0% · Net -0.2%

ROE

FY2025 · ROE -0.4%

Gross margin45.9%

Operating margin2.0%

Net margin-0.2%

Return on assets-0.1%

EBITDAUSD 288.5M

Each USD of equity lost 0 cents this year.

Cash & shareholders

USD 24.9M

returned in FY2025 · dividends + net buybacks

Free cash flow $M

FY2025 · FCF 43.3

Net buybacks $M Dividends $M

FY2025 · Dividends 22.8 · Net buybacks 2.1

Dividends paidUSD 22.8M

Net buybacksUSD 2.1M

Share of profit-289.5%

Consecutive raises—

USD 22.8M in dividends and USD 2.1M in buybacks went back to shareholders in a year without profit.

Total assetsUSD 6.2B

EquityUSD 2.5B

CashUSD 298.8M

Gross debtUSD 1.9B

Net debtUSD 1.6B

Current ratio1.73×

Net debt stands at 63% of equity.

The 17-year record

17 fiscal years

Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Revenue $B	3.4	3.4	3.0	2.5	2.4	2.0	2.1	1.9	1.8	1.6	1.6	1.8	1.8	1.8	1.7	1.3	1.1
Operating income $B	0.1	0.3	0.4	0.4	0.4	0.2	0.3	0.3	0.2	0.2	0.1	0.1	0.1	0.2	0.2	0.2	0.1
EBITDA $B	0.3	0.4	0.6	0.5	0.5	0.3	0.4	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Income tax $B	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0
Net income $B	−0.0	0.1	0.4	0.3	0.3	0.2	0.2	0.2	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Free cash flow $B	0.0	0.1	0.2	0.1	0.2	0.2	0.1	0.2	0.1	0.1	0.2	0.1	0.1	0.1	0.0	0.1	0.1
EPS, diluted $	−0.15	0.76	2.90	1.99	1.81	1.02	1.26	1.14	0.49	0.95	0.60	0.33	0.48	0.46	0.55	0.58	0.49
Dividend / sh $	·	0.20	0.20	0.20	0.16	0.16	0.16	0.16	0.16	0.16	·	·	·	·	·	·	·
Payout %	−265	27	7	10	9	16	13	14	32	17	·	·	·	·	·	·	·
ROE %	−0.4	7.2	34.3	27.2	27.3	16.9	21.9	22.2	11.1	21.7	13.6	7.0	10.3	11.7	16.1	18.2	·
Shares out B	0.15	0.15	0.15	0.15	0.15	0.15	0.15	0.16	0.16	0.16	0.17	0.17	0.17	0.17	0.17	0.17	·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance

Company facts, as filed

How we verify · 0 failures in 83 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 12 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures

ActivityLaboratory Analytical Instruments

Listed onNASDAQ

Incorporated inDelaware

Fiscal year endsDecember 31

Data on record since2009